Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

BACKGROUND: At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19). After emergency use of the vaccine was authorized, the protocol was amended to include an open-label phase...

Descripción completa

Detalles Bibliográficos
Autores principales: El Sahly, Hana M., Baden, Lindsey R., Essink, Brandon, Doblecki-Lewis, Susanne, Martin, Judith M., Anderson, Evan J., Campbell, Thomas B., Clark, Jesse, Jackson, Lisa A., Fichtenbaum, Carl J., Zervos, Marcus, Rankin, Bruce, Eder, Frank, Feldman, Gregory, Kennelly, Christina, Han-Conrad, Laurie, Levin, Michael, Neuzil, Kathleen M., Corey, Lawrence, Gilbert, Peter, Janes, Holly, Follmann, Dean, Marovich, Mary, Polakowski, Laura, Mascola, John R., Ledgerwood, Julie E., Graham, Barney S., August, Allison, Clouting, Heather, Deng, Weiping, Han, Shu, Leav, Brett, Manzo, Deb, Pajon, Rolando, Schödel, Florian, Tomassini, Joanne E., Zhou, Honghong, Miller, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482810/
https://www.ncbi.nlm.nih.gov/pubmed/34551225
http://dx.doi.org/10.1056/NEJMoa2113017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482810/
https://www.ncbi.nlm.nih.gov/pubmed/34551225
http://dx.doi.org/10.1056/NEJMoa2113017

Ejemplares similares